My College Roomie Leads the Fight Against Merck

Photo: Kevin Bixby (far left) and Dave Buchanan (far right) pictured as members of the University of Delaware's top beer pong team circa 1989
Believe it or not, the former college roomate of editor Dr. Kevin Bixby leads the fight against Merck. David Buchanan (who learned a lot from me) is a partner with Seeger Weiss of New York City. He was also involved in lawsuits against Vioxx, Apple Computers, IBM , Daimler and even Martha Stewart. Here is a little more info on the recent Fosamax case

A New York based lawfirm announced earlier this year that it is investigating claims against Merck & Co. (NYSE:MRK - News) for Fosamax-related injuries, including reports of osteonecrosis of the jaw. Fosamax, marketed by Merck, is indicated for the treatment and prevention of osteoporosis (thinning of the bones) in men and women. Recent studies, however, suggest a link between the use of bisphosphonates, such as Fosamax, and osteonecrosis of the jaw, also known as "jaw death.'' This condition is associated with the interference of the blood supply to the bone and the consequential damage that occurs. Osteonecrosis of the jaw can be extremely painful and may lead to additional complications, such as infection, breakdown of the jawbone, and ulcerations in the lining of the mouth. It is not known if ceasing the use of Fosamax can lower the risk of osteonecrosis of the jaw, as the bisphosphonate medications metabolize slowly and remain in the bones for many years.

This is another in a serious of stories on personal injury, malpractice and related articles.